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1003-94 Rheolytic Thrombectomy for the Treatment of Acute 
Myocardial Infarction in Patients With Angiographic 
Large Thrombus Burden: One-Year Results of the 
VeGAS 2 Acute Myocardial Infarction Registry
Jose A. Silva, Stephen R. Ramee, David Cohen, Joseph P. Carrozza, Jeffrey J. Popma, 
Kim Dandreo, Alexandra A. Lansky, Donald S. Baim, Barry S. George, Daniel J. 
McCormick, Cindy M. Setum, Richard E. Kuntz, The VeGAS 2 Investigators, Ochsner 
Clinic Foundation, New Orleans, LA
Background. The treatment of acute myocardial infarction (MI), in patients (pts) with
angiographic evidence of large thrombus burden is difficult. There are scarce data in the
literature addressing the optimal management of this high-risk patient population.
Methods and Results. This prospective study enrolled 107 pts (age, 61 ± 12 years, 71%
males) presenting with acute ST elevation MI within 24 hours of symptoms onset and
angiographic evidence of thrombus. The culprit lesion was located in a native coronary
artery in 74.5%, and in a bypass graft in 25.5%. Abciximab was used in 42.1% of the pts.
Thrombus area decreased from 97 ± 67 mm2 at baseline to 17 ± 11 mm2 post thrombec-
tomy, to 3 ± 12 mm2 after final treatment. TIMI 3 coronary flow was obtained in 78% after
thrombectomy and 87% after final treatment. Procedure success (residual diameter
stenosis < 50%, and TIMI 3 flow post-procedure in the absence of in-hospital death,
emergent CABG and recurrent Q-wave MI) was obtained in 77% of the patients. Bleeding
and vascular complications occurred in 13% and 11% respectively, abrupt or subacute
closure in 6.6%, and distal embolization in 6.8%. The in-hospital death and major cardio-
vascular events (death, Q-wave MI, surgical or percutaneous target lesion revasculariza-
tion [TLR] or CVA) (MACE) rates were 7.8% and 13% respectively. There were no
additional MACE at 30-follow-up after discharge. At one-year follow-up there was an
additional 4% mortality, 7.4% TLR, and 1.8% CVA , but no Q-wave MI.
Conclusion. Patients presenting with acute MI and angiographic evidence of large
thrombus burden are at higher risk for mortality and MACE compared with historical con-
trols. Rheolytic thrombectomy is very effective in removing thrombus and restoring TIMI 3
coronary flow in this high-risk patient population.
1003-95 Thrombus Aspiration for the Treatment of No-Reflow 
Phenomenon Complicating Primary Angioplasty for 
Acute Myocardial Infarction
Imad Sheiban, Claudio Moretti, Kumar Prathap, Filippo Sciuto, Andra Gagnor, Pierluigi 
Omedè, Alessandra Truffa, Walter Grosso Marra, Ahmed Shoheib, Maria Teresa 
Lucciola, Gianpaolo Trevi, University of Torino, Torino, Italy
Background: Primary angioplasty (PCI) for acute myocardial infarction (AMI) can be com-
plicated by no-reflow or slow-flow phenomenon in nearly 20% of patients. It’s not clear
which is the best strategy to use when such phenomenon occurs. Intracoronary adenos-
ine and GP IIb/IIIa antagonists have been suggested but their efficacy is not well estab-
lished. In this study we report our experience with the use of thrombus aspiration as an
approach for the treatment of no-reflow complicating primary PCI for AMI.
Methods: Among 239 consecutive primary PCI for AMI performed in our Center, 46
(19%) were complicated by no-reflow or slow-flow phenomenon. All pts received intracor-
onary GP IIb/IIIa antagonist (abiciximab) soon after culprit lesion was crossed by the
guide wire. No-reflow or slow-flow phenomenon occurred soon after balloon inflation or
stent deployment at the site of target lesion. Intracoronary adenosine (45 to 60 ug ) was
given in all 46 pts but no persistent improvement was observed. Thus , thrombus aspira-
tion by Rescue system ( Boston Scientific ) or by Diver CE catheter (Invatec srl) was
attempted in all 42 pts. At least three passages of the aspiration catheter along the culprit
vessel were performed in all pts.
Results: Blood flow was restored in 38 patients (82%) with TIMI II/III flow. In 20 pts
(52.6%) thrombotic material was aspirated from the culprit vessel as was confirmed by
histological analysis. In 6 pts a persistent TIMI I flow was observed after repeated aspira-
tion. No material was aspirated from the culprit vessel in these pts. In 2 pts thrombus
aspiration was not successful (persistent no-reflow). No procedural complications device-
related occurred . All pts were discharged within 7 days following the procedure. Clinical
follow-up was available in all patients . All were event free at 7± 3 months .
Conclusions: These data suggest that no-reflow phenomenon during primary-PCI in AMI
pts can be related to massive microembolization of thrombus fragments which might also
increase blood viscosity contributing to no-reflow phenomenon. Aspiration of thombotic
debris and blood from the treated vessel seems to be an effective approach to restore
blood flow and confers an excellent clinical outcome.
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1021-77 Diabetic Patients With Acute Coronary Syndromes Were 
Undertreated and Had Worse One-Year Outcome
Raymond T. Yan, Andrew T. Yan, Mary Tan, Lawrence Leiter, Chi-Ming Chow, David H. 
Fitchett, Ronald Fowlis, Irene Janzen, Anatoly Langer, Shaun G. Goodman, Canadian 
Heart Research Centre, Toronto, ON, Canada, University of Toronto, Toronto, ON, 
Canada
Background: Previous studies reported different characteristics, management and out-
come between diabetic and non-diabetic patients with myocardial infarction (MI). How-
ever, the relationship between diabetes and the entire spectrum of acute coronary
syndromes (ACS) is less clear.
Methods: The ACS Registry was a prospective observational study enrolling less
selected patients with suspected ACS from 51 Canadian centres. In-hospital data were
recorded on standard case report forms and one-year outcome was ascertained by stan-
dardized telephone interviews. We examined patients with confirmed ACS by pre-existing
diabetic status for differences in treatment and outcome.
Results: Of 4578 ACS patients, 1149 (25.1%) had diabetes; they were older, had more
cardiovascular risk factors, comorbidities and prior revascularization. (See Table) 
In multivariable analyses controlling for baseline characteristics, diabetes was indepen-
dently associated with higher 1-year mortality (odds ratio 1.52; 95% CI: 1.18 to1.95; 
P=0.001); this did not change significantly after further adjustment for use of medications 
and revascularization.
Conclusions: Diabetic patients with ACS represented a higher risk subgroup with more 
comorbidities and prior revascularization, but were less likely to receive effective medica-
tions or be considered for revascularization. In view of their two-fold increase in mortality, 
there remains an opportunity to optimize the use of evidence-based therapies in diabetic 
patients.
1021-78 Increased In-Hospital Mortality After Acute Myocardial 
Infarction in Patients With Impaired Fasting Glucose
Marianne Zeller, Marie-Claude Brindisi, Gilles Dentan, Yves Laurent, Jean-Claude Beer, 
Luc Janin-Manificat, Hamid Makki, Isabelle L'Huillier, Jack Ravisy, Mohamed Jolak, Jean-
Eric Wolf, Bruno Verges, Yves Cottin, The RICO Survey Working Group, University 
Hospital, Dijon, France
Objectives : In-hospital mortality after acute MI has not yet been evaluated in patients
belonging to the new category of Impaired Fasting Glucose level (IFG), as defined by the
American Diabetes Association. Methods : Between 1rst January 2001 and 31rst July
2003, all patients hospitalized with acute MI in one region of eastern France participating
to RICO survey were included in the study. Fasting blood glucose was measured <3 days
after admission. Patients were grouped based on FG concentration : Diabetes Mellitus
(DM) (FG > 7 mm/L or clinical history of DM) ; IFG (FG 6.1 to 7 mmole/L) ; NFG (normal
FG < 6.1 mmole/L). Results : Among the 999 included in the study, 381 (38%) had DM,
145 (15%) IFG and 473 (47%) NFG. Age, cardiovascular risk factors, renal function and
MI characteristics were not different between IFG and NFG patients. There was a 2 fold
increase of in-hospital mortality in IFG group when compared to normal glucose group (8
vs 4 %, p<0.001). A significant increase in cardiogenic shock (12 vs 6%, p<0.001) and in
ventricular arrhythmia (15 vs 9%, p<0.001) was observed in IFG group, as compared to
NFG group. Data from the mutivariate analysis showed that increased cardiogenic shock
(p=0.007) and ventricular arrhythmia (p=0.014) mostly explained augmented in-hospital
mortality in patients with IFG. In our population, IFG, after adjustment for potential con-
founding factors (age, sex, anterior location, LVEF, CK, reperfusion, multivessel disease
and cardiogenic shock), was an independent predictive factor for cardiogenic shock
Non-diabetic
(N=3429)
Diabetic
(N=1149)
P-value
In-hospital Management (%)
Catheterization 41.0 36.4 0.003
PCI 18.0 12.7 <0.001
Thrombolytics/1°PCI (eligible patients) 62.8 50.3 <0.001
Aspirin 93.2 88.9 <0.001
Heparin 91.4 89.3 0.032
Glycoprotein IIb/IIIa inhibitor 7.6 5.2 0.005
Outcome (%)
In-hospital mortality 1.8 3.9 <0.001
1-year mortality 7.9 14.4 <0.001
